 |
|
Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future
Asako Nogami, Masato Yoneda, Michihiro Iwaki, Takashi Kobayashi, Yasushi Honda, Yuji Ogawa, Kento Imajo, Satoru Saito, Atsushi Nakajima
Clin Mol Hepatol. 2023;29(Suppl):S123-S135. Published online 2022 Dec 12 DOI: https://doi.org/10.3350/cmh.2022.0357
|
|
Citations to this article as recorded by
 Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future
Lynna Alnimer, Mazen Noureddin
Clinical and Molecular Hepatology.2023; 29(2): 394. CrossRef Application of attenuation imaging for the detection of fatty liver in potential liver donors
Jae Seok Bae, Dong Ho Lee, Kyung-Suk Suh, Kwang-Woong Lee, Nam-Joon Yi, Suk Kyun Hong
European Journal of Radiology.2023; 166: 110958. CrossRef Editorial: Will MRI‐PDFF become the new standard for steatosis assessment in NAFLD?
Angeliki Pappa, Tobias Wenzl
Alimentary Pharmacology & Therapeutics.2023; 58(3): 364. CrossRef
|